BioSpace News Archive

BioDroneTM next-generation drug delivery platform honored for excellence alongside other innovators and innovations in the Health, Medical & Biotech category

The study will assess the role of Huawei’s wearable technology to detect atrial fibrillation in post-stroke patients

Monod Bio, a life sciences company developing custom diagnostic biosensors that emit light to detect specific analytes of interest, today announced a publication in Nature highlighting its LuxSit de novo luciferase technology licensed from the University of Washington (UW).

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced an update on preliminary safety and efficacy data from its ongoing FORTIS Phase1/2 clinical trial evaluating the safety, tolerability and exploratory efficacy of investigational AT845 in adults with late-onset Pompe disease (LOPD).

Societal CDMO, Inc. announced that the company will release financial results for the fourth quarter and year-end 2022 after the market close on Wednesday, March 1, 2023.

Imara Inc. announced the results of the special meeting of its stockholders held on February 22, 2023.

Homology Medicines, Inc. announced the presentation of preclinical data that supports the targeted, prophylactic immunosuppression regimen in the ongoing pheEDIT gene editing clinical trial in adults with phenylketonuria and juMPStart gene therapy trial in adults with Hunter syndrome.

Corium, LLC announced today publication of the results from a 12-month, open-label, phase 3 safety study of AZSTARYS (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]), which is indicated for treatment of attention-deficit hyperactivity disorder (ADHD) in people ages six and older.

The CMT Research Foundation ( CMTRF ), a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease*, today announced a partnership with Nanite, Inc., a Boston-based biotechnology company developing SAYER ™ , an AI-driven gene delivery platform focused on polymer nanoparticles (PNPs). As part of the partnership agreement, Nanite will design delivery vehicles for genetic medicines to Schwann cells via PNPs, an emerging technolo

Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in March.